News

Stories

See all

Updates: Lilly's Global COVID-19 Response

View Story

Lilly Accelerates Cancer R&D with Speed and Precision

View Story

Testing for the Novel Coronavirus

View Story

Genomic Testing in Cancer

View Story

Cancer Care Beyond Medicine

View Story

three Lilly scientists talking in a lab

DiversityInc No. 3 Ranking Highlights Our Inclusive Culture

View Story


  1. 1

Press Releases

See all

Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

June 1, 2020

Tags |  Product

- Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA - INDIANAPOLIS , June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S.




Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

June 1, 2020

Tags |  Product

- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera   - The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June   - Should Phase 1




Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

May 29, 2020

Tags |  Product

CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study   CYRAMZA regimen reduced the risk of disease progression or death




Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease

May 28, 2020

Tags |  Product

The first and only approved diagnostic agent to image tau neurofibrillary tangles in the brain INDIANAPOLIS , May 28, 2020 /PRNewswire/ -- TAUVID ™ , a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and